The first peptide to attract attention was GIP, soon followed by GLP-1 because of its more suitable features as a pharmacological agent for improvement of glucose control and body-weight reduction in people with type 2 diabetes [4]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.